NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free CSTL Stock Alerts $23.15 +0.12 (+0.52%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$22.71▼$23.2650-Day Range$18.84▼$24.9452-Week Range$12.07▼$25.91Volume246,802 shsAverage Volume242,348 shsMarket Capitalization$639.17 millionP/E RatioN/ADividend YieldN/APrice Target$30.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Castle Biosciences alerts: Email Address Castle Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.0% Upside$30.80 Price TargetShort InterestHealthy4.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 4 Articles This WeekInsider TradingSelling Shares$1.08 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.70) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector481st out of 905 stocksMedical Laboratories Industry11th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCastle Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Castle Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.67% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 10.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 3.8 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Castle Biosciences this week, compared to 3 articles on an average week.Search Interest6 people have searched for CSTL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,080,010.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Castle Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to decrease in the coming year, from ($1.70) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -20.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -20.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Castle Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from these levels.But there are at least 10 different coins that I like even better. About Castle Biosciences Stock (NASDAQ:CSTL)Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More CSTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSTL Stock News HeadlinesJune 6 at 7:54 AM | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $55,411.20 in StockJune 7 at 6:14 AM | americanbankingnews.comDerek J. Maetzold Sells 2,368 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockMay 30, 2024 | businesswire.comCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceMay 29, 2024 | businesswire.comNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisMay 15, 2024 | businesswire.comCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceMay 14, 2024 | finance.yahoo.comCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024May 14, 2024 | businesswire.comCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024May 10, 2024 | finance.yahoo.comCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"May 10, 2024 | businesswire.comCastle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”May 8, 2024 | finance.yahoo.comLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultMay 7, 2024 | finance.yahoo.comWall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should KnowMay 5, 2024 | finance.yahoo.comEarnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 5, 2024 | msn.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call TranscriptMay 3, 2024 | businesswire.comDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckMay 2, 2024 | investorplace.comCSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | markets.businessinsider.comCastle Biosciences earnings: here's what Wall Street expectsMay 2, 2024 | finance.yahoo.comCastle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...May 2, 2024 | businesswire.comCastle Biosciences Reports First Quarter 2024 ResultsApril 30, 2024 | finance.yahoo.comCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaApril 30, 2024 | businesswire.comCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT MelanomaApril 27, 2024 | investing.comCastle Biosciences CEO Derek Maetzold sells shares worth over $22,000April 27, 2024 | seekingalpha.comCSTL Castle Biosciences, Inc.April 18, 2024 | investing.comCastle Biosciences CEO sells over $100k in company stockApril 17, 2024 | finance.yahoo.comWe're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash BurnApril 11, 2024 | businesswire.comCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024See More Headlines Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/08/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees610Year FoundedN/APrice Target and Rating Average Stock Price Target$30.80 High Stock Price Target$37.00 Low Stock Price Target$25.00 Potential Upside/Downside+33.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,470,000.00 Net Margins-12.28% Pretax Margin-12.23% Return on Equity-7.91% Return on Assets-6.95% Debt Debt-to-Equity Ratio0.02 Current Ratio9.25 Quick Ratio9.02 Sales & Book Value Annual Sales$219.79 million Price / Sales2.91 Cash FlowN/A Price / Cash FlowN/A Book Value$14.54 per share Price / Book1.59Miscellaneous Outstanding Shares27,610,000Free Float25,619,000Market Cap$639.17 million OptionableOptionable Beta0.95 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Derek J. Maetzold (Age 62)Founder, CEO, President & Director Comp: $1.45MMr. Frank Stokes (Age 53)CFO & Treasurer Comp: $849.36kMs. Kristen M. Oelschlager R.N. (Age 56)Chief Operating Officer Comp: $782.7kMr. Tobin W. Juvenal (Age 64)Chief Commercial Officer Comp: $782.7kCamilla ZuckeroVice President of Investor Relations & Corporate AffairsMs. Alice Bahner IzzoSenior Vice President of MarketingMr. Kevin DomanVice President of SalesMs. Keli GreenbergVP of Human Resources & Executive Director of Human ResourcesDr. Robert W. Cook Ph.D. (Age 52)Senior Vice President of Research & Development Dr. Matthew Goldberg M.D.Senior Vice President of MedicalMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHMyriad GeneticsNASDAQ:MYGNFortreaNASDAQ:FTREVeracyteNASDAQ:VCYTViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsDerek J MaetzoldSold 2,368 sharesTotal: $55,411.20 ($23.40/share)Jacobs Levy Equity Management Inc.Sold 4,885 shares on 5/16/2024Ownership: 1.927%Invenomic Capital Management LPSold 5,098 shares on 5/16/2024Ownership: 0.604%California State Teachers Retirement SystemSold 1,282 shares on 5/16/2024Ownership: 0.092%Public Employees Retirement System of OhioSold 6,818 shares on 5/15/2024Ownership: 0.338%View All Insider TransactionsView All Institutional Transactions CSTL Stock Analysis - Frequently Asked Questions Should I buy or sell Castle Biosciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks. What is Castle Biosciences' stock price target for 2024? 4 brokers have issued 12-month target prices for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $37.00. On average, they anticipate the company's share price to reach $30.80 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts. How have CSTL shares performed in 2024? Castle Biosciences' stock was trading at $21.58 on January 1st, 2024. Since then, CSTL stock has increased by 7.3% and is now trading at $23.15. View the best growth stocks for 2024 here. Are investors shorting Castle Biosciences? Castle Biosciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,290,000 shares, a decline of 10.4% from the April 30th total of 1,440,000 shares. Based on an average trading volume of 255,900 shares, the short-interest ratio is presently 5.0 days. View Castle Biosciences' Short Interest. When is Castle Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our CSTL earnings forecast. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.28. The company had revenue of $72.97 million for the quarter, compared to analysts' expectations of $68.34 million. Castle Biosciences had a negative trailing twelve-month return on equity of 7.91% and a negative net margin of 12.28%. What ETF holds Castle Biosciences' stock? iShares U.S. Healthcare Providers ETF holds 34,483 shares of CSTL stock, representing 0.11% of its portfolio. What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $237.6 million. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC). When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Castle Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (9.29%), Principal Financial Group Inc. (5.58%), Vanguard Group Inc. (5.41%), Bellevue Group AG (4.42%), Jacobs Levy Equity Management Inc. (1.93%) and Acadian Asset Management LLC (0.76%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Kristen M Oelschlager, Tiffany Olson and Tobin W Juvenal. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CSTL) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
